Overview

Drug Use Investigation Of Gabapentin

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The objective of the this surveillance is to collect information about 1)adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Gabapentin
gamma-Aminobutyric Acid